TITLE

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France

AUTHOR(S)
Descamps, Diane; Chaix, Marie-Laure; Montes, Brigitte; Pakianather, Sophie; Charpentier, Charlotte; Storto, Alexandre; Barin, Francis; Santos, Georges Dos; Krivine, Anne; Delaugerre, Constance; Izopet, Jacques; Marcelin, Anne-Geneviève; Maillard, Anne; Morand-Joubert, Laurence; Pallier, Coralie; Plantier, Jean-Christophe; Tamalet, Catherine; Cottalorda, Jacqueline; Desbois, Delphine; Calvez, Vincent
PUB. DATE
December 2010
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Dec2010, Vol. 65 Issue 12, p2620
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France. Methods Resistance mutations were sought in samples from 530 newly diagnosed HIV-1-infected patients from October 2006 to March 2007. Protease and reverse transcriptase mutations were identified from the 2007 Stanford Resistance Surveillance list. Results Reverse transcriptase and protease resistance mutations were determined in 466 patients with duration of seropositivity <5 years. 42% of patients were infected with non-B subtype strains (CRF02 18.3%). The overall prevalence of viruses with protease or reverse transcriptase mutations was 10.6% (95% confidence interval 6.7–16.3). The prevalence of protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor resistance-associated mutations was 4.7%, 5.8% and 2.8%, respectively. Frequency of resistance was not different in patients infected with B (9.5%) and non-B (CRF02 7.8% and other 11.2%) subtypes. Baseline characteristics such as gender, age, transmission group, country of transmission, disease stage, CD4 counts and viral load were not associated with the prevalence of transmitted drug resistance. Conclusions In France in 2006/2007, the prevalence of transmitted drug-resistant variants was 10.6%. Prevalence of transmitted drug resistance was comparable in B and non-B subtypes. Prevalence of non-B subtypes is still rising.
ACCESSION #
55117993

 

Related Articles

  • Incarceration Predicts Virologic Failure for HIVInfected Injection Drug Users Receiving Antiretroviral Therapy. Westergaard, Ryan P.; Kirk, Gregory D.; Richesson, Douglas R.; Galai, Noya; Mehta, Shruti H. // Clinical Infectious Diseases;10/1/2011, Vol. 53 Issue 7, p725 

    Background. Incarceration may lead to interruptions in antiretroviral therapy (ART) for persons receiving treatment for human immunodeficiency virus (HIV) infection. We assessed whether incarceration and subsequent release were associated with virologic failure for injection drug users (IDUs)...

  • Pitfalls of HIV genotypic tropism testing after treatment interruption. Wirden, Marc; Soulié, Cathia; Fourati, Slim; Valantin, Marc Antoine; Simon, Anne; Ktorza, Nadine; Tubiana, Roland; Bonmarchand, Manuela; Schneider, Luminita; Calvez, Vincent; Katlama, Christine; Marcelin, Anne-Genevieve // Journal of Antimicrobial Chemotherapy (JAC);Jan2013, Vol. 68 Issue 1, p188 

    Objectives The genotypic method is reliable enough for the determination of tropism and largely preferred in Europe. However, careful interpretation is essential when assessing HIV genotypic resistance during treatment interruption (TI) due to the possible disappearance of resistant strains. The...

  • HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of greater than 50 Copies/mL Receiving Combination Therapy. Hermankova, Monika; Ray, Stuart C.; Ruff, Christian; Powell-Davis, Monique; Ingersoll, Roxann; D'Aquila, Richard T.; Quinn, Thomas C.; Siliciano, Janet D.; Siliciano, Robert F.; Persaud, Deborah // JAMA: Journal of the American Medical Association;7/11/2001, Vol. 286 Issue 2, p196 

    Presents a study to determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression while receiving highly active antiretroviral therapy. Design and setting; Patients; Main outcome measure; Results; Conclusions.

  • High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. Frange, Pierre; Galimand, Julie; Goujard, Cécile; Deveau, Christiane; Ghosn, Jade; Rouzioux, Christine; Meyer, Laurence; Chaix, Marie-Laure // Journal of Antimicrobial Chemotherapy (JAC);Jul2009, Vol. 64 Issue 1, p135 

    Objectives To estimate the frequency of viruses with X4 or dual-X4/DM tropism from peripheral blood mononuclear cells (PBMCs) of 390 human immunodeficiency virus type 1 (HIV-1) subtype-B patients diagnosed at the time of primary HIV-1 infection (PHI) between 1996 and 2007 and enrolled in the...

  • Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. Pernas, Mar�a; Casado, Concepci�n; Arcones, Carolina; Llano, Anuska; S�nchez-Merino, V�ctor; Mothe, Beatriz; Vicario, Jos� L.; Grau, Eulalia; Ruiz, Lidia; S�nchez, Jorge; Telenti, Amalio; Yuste, Elo�sa; Brander, Christian; L�pez- Gal�ndez, Cecilio // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objective: To study the causes for the lack of clinical progression in a superinfected HIV-1 LTNP elite controller patient. Methodology and Principal Findings: We studied host genetic, virological and immunological factors associated with viral control in a SI long term non progressor elite...

  • HIV in Correctional Facilities: Role of Self-Report in Case Identification. Lyons, Thomas; Goldstein, Paul; Kiriazes, Jean // AIDS Patient Care & STDs;Feb2006, Vol. 20 Issue 2, p93 

    For treatment of HIV/AIDS in jails and prisons to be effective, these institutions must identify as many HIV-positive inmates as they can. We compare HIV status among a drug-addicted jail population determined through a physical examination and a voluntary HIV testing program, with self-reported...

  • Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. Pernas, María; Casado, Concepción; Arcones, Carolina; Llano, Anuska; Sánchez-Merino, Víctor; Mothe, Beatriz; Vicario, José L.; Grau, Eulalia; Ruiz, Lidia; Sánchez, Jorge; Telenti, Amalio; Yuste, Eloísa; Brander, Christian; López- Galíndez, Cecilio // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objective: To study the causes for the lack of clinical progression in a superinfected HIV-1 LTNP elite controller patient. Methodology and Principal Findings: We studied host genetic, virological and immunological factors associated with viral control in a SI long term non progressor elite...

  • The Epidemic Comes Home: b. The Ethical Dimension: "Don't Tell Me on Friday". Richards, Thomas // AIDS Reader (Branden Publishing);1988, p232 

    The article presents a reprint of the article "Don't Tell Me on Friday," by Thomas Richards, which appeared on the April 5, 1986 issue of the British Medical Journal. The author relates his experience on being positive for antibodies to human T cell lymphotropic virus III. He was shocked upon...

  • Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression Snedecor, Sonya J. // Bulletin of Mathematical Biology;Nov2005, Vol. 67 Issue 6, p1315 

    Abstract: Recent advances in the chemotherapy of HIV infection have been successful in delaying the progression of disease in many patients and are responsible for the decline in HIV-related deaths in the United States. Yet, there are many patients who fail to maintain suppressed viral loads on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics